Lenvatinib: Role in thyroid cancer and other solid tumors

Highlights • We review advanced thyroid cancer (TC) etiology and signaling pathway mutations. • We review the mechanism of action and role of tyrosine kinase inhibitors (TKIs). • Lenvatinib, a multitargeted TKI, has broad antitumor and antiangiogenic activity. • We review phase III radioactive iodin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment reviews 2016-01, Vol.42, p.47-55
Hauptverfasser:	Cabanillas, Maria E, Habra, Mouhammed Amir
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced Animals Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carboplatin - administration & dosage Carcinoma - drug therapy Carcinoma - enzymology Carcinoma - therapy Clinical Trials as Topic Combined Modality Therapy Differentiated Everolimus - administration & dosage Hematology, Oncology and Palliative Medicine Humans Infant Iodine Radioisotopes - therapeutic use Medullary Mice Molecular Targeted Therapy Multicenter Studies as Topic Multikinase Neoplasm Proteins - antagonists & inhibitors Neoplasms - drug therapy Neoplasms - enzymology Paclitaxel - administration & dosage Phenylurea Compounds - administration & dosage Phenylurea Compounds - adverse effects Phenylurea Compounds - pharmacology Phenylurea Compounds - therapeutic use Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Quinolines - administration & dosage Quinolines - adverse effects Quinolines - pharmacology Quinolines - therapeutic use Receptors, Growth Factor - antagonists & inhibitors Refractory Signal Transduction - drug effects Survival Thyroid Neoplasms - drug therapy Thyroid Neoplasms - enzymology Thyroid Neoplasms - therapy Thyroidectomy Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • We review advanced thyroid cancer (TC) etiology and signaling pathway mutations. • We review the mechanism of action and role of tyrosine kinase inhibitors (TKIs). • Lenvatinib, a multitargeted TKI, has broad antitumor and antiangiogenic activity. • We review phase III radioactive iodine-refractory differentiated TC results. • Lenvatinib shows superior progression-free survival and overall response rate.
ISSN:	0305-7372 1532-1967
DOI:	10.1016/j.ctrv.2015.11.003